103 results on '"Moins‐Teisserenc, Helene"'
Search Results
2. Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study
3. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study
4. Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients
5. Human-Derived α1-Antitrypsin is Still Efficacious in Heavily Pretreated Patients with Steroid-Resistant Gastrointestinal Graft-versus-Host Disease
6. Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study
7. Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma
8. Targeting TGF-β Activation in Cutaneous T-Cell Lymphomas
9. Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients
10. CD38 targeting in aggressive, treatment-refractory cutaneous T-cell lymphomas
11. Tre-P-07 - Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study
12. Tre-P-08 - Granulomatous rash associated with mogamulizumab mimicking mycosis fungoides: a case series
13. Hist-O-03 - Large cell transformation is an independent prognostic factor in Sézary syndrome: a retrospective analysis of 117 cases
14. Bio-O2-03 - Quantifying response to various treatments using the revisited blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker
15. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy
16. P-205 - Toxic epidermal necrolysis possibly associated with mogamulizumab in a patient with Sézary syndrome
17. O-144 - Lacutamab in patients with mycosis fungoides: efficacy results according to updated lymph node classification in the TELLOMAK study
18. O-103 - CD38 targeting in aggressive, treatment-refractory cutaneous T-cell lymphomas
19. CD158k Is a Reliable Marker for Diagnosis of Sézary Syndrome and Reveals an Unprecedented Heterogeneity of Circulating Malignant Cells
20. CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas
21. Cytokine expression and cytokine-based T cell profiling in South Indian rheumatoid arthritis
22. Long-Term Immune Reconstitution and Infection Burden after Mismatched Hematopoietic Stem Cell Transplantation
23. Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma
24. Chapitre 28 - Les mécanismes de l'alloréactivité, des rejets de greffe et de la réaction du greffon contre l'hôte
25. Chapitre 25 - Les mécanismes de l'immunosurveillance antitumorale
26. CCR8 is a new therapeutic target in cutaneous T-cell lymphomas
27. ESDR464 - CCR8 is a new therapeutic target in cutaneous T-cell lymphomas
28. Patterns of Cytomegalovirus Reactivation Are Associated with Distinct Evolutive Profiles of Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation
29. NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation
30. Flow cytometry for the assessment of blood tumour burden in cutaneous T‐cell lymphoma: towards a standardized approach
31. Lymphopenia Confers Poorer Prognosis in Myelodysplastic Neoplasms (MDS) with Very Low and Low IPSS-M
32. Lacutamab in Patients with Relapsed and Refractory Sèzary Syndrome: Results from the Tellomak Phase 2 Trial
33. Immunological profile of Fanconi anemia: A multicentric retrospective analysis of 61 patients
34. Serum IgG2 levels predict long-term protection following pneumococcal vaccination in systemic lupus erythematosus (SLE)
35. BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis
36. Identification of multiple HLA-A*0201-restricted cruzipain and FL-160 CD8 + epitopes recognized by T cells from chronically Trypanosoma cruzi-infected patients
37. Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial
38. Chapitre 24 - Les mécanismes de l'immunosurveillance antitumorale
39. Chapitre 27 - Les mécanismes de l'alloréactivité, des rejets de greffe et de la réaction du greffon contre l'hôte
40. Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity
41. La transformation en grandes cellules est un facteur pronostique indépendant dans le syndrome de Sézary : étude rétrospective de 117 cas
42. Performances du séquençage haut débit du TCR-bêta pour le diagnostic de lymphome T cutané
43. Éruptions granulomateuses associées au mogamulizumab mimant un mycosis fongoïde. Six observations
44. Mycosis fongoïde chalazodermique étude clinique rétrospective de 8 cas du GFELC
45. Association d’une leucémie à grands lymphocytes granuleux et d’un lymphome T cutané aux caractéristiques phénotypiques atypiques
46. Early Immune Reconstitution after Hematopoietic Stem Cell Transplantation for Adolescents and Adults with Sickle Cell Disease
47. Tre-O2-10 - Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas
48. Tre-O2-05 - Macrophage-derived CXCL9 and CXCL11 recruit CD8 T cells in skin and provide long-term disease control in mogamulizumab-treated CTCL patients
49. Tre-O2-07 - Lacutamab in patients (pts) with advanced mycosis fungoides (MF) according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial
50. Tre-O2-04 - Mogamulizumab induces long term immune restoration and reshapes tumoral heterogeneity in Sézary syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.